Effects of Desloratadine Citrate Disodium combined with Budesonide suspension on serum IgE, EOS and inflammatory factors in patients with CRS after endoscopic sinus surgery

Objective: To observe the clinical application of Desloratadine Citrate Disodium combined with Budesonide suspension in patients with chronic rhinosinusitis CRS after endoscopic sinus surgery, and analyze the change of serum immunoglobulin E (IgE), eosinophils (EOS) and inflammatory factors level in patients. Method: A total of 90 cases of patients with CRS were randomly divided into control group (n=45) and observation group (n=45) according to the lottery method. Both groups were treated with endoscopic sinus surgery. On the basis of this, control group was given Budesonide suspension and observation group was treated with Desloratadine Citrate Disodium combined with Budesonide suspension. The change of serum IgE, EOS and inflammatory factors were measured before and after operation in all subjects. Results: There was no significant difference in IgE and EOS levels between control group and observation group before treatment. After treatment, the levels of serum IgE and EOS in the two groups were significantly lower than those before treatment. Moreover, after treatment, observation group was lower than control group, and the difference was significant. There was no significant difference in inflammatory factors level between control group and observation group before treatment. After treatment, the levels of serum IL-6, IL-8, TNF-α and hs-CRP were significantly lower than those before treatment. After treatment, observation group was lower than the control group in the same period, the difference was significant. Conclusion:Combined Desloratadine Citrate Disodium treatment for CRS patients on the basis of endoscopic sinus surgery and Budesonide Nasal Spray treatment, it can more effectively reduce serum IgE and EOS levels, decrease the inflammatory response. Therefore it was a potential effective treatment for patients with CRS.

miR-124对宫颈癌Hela细胞放射敏感性的影响及其机制探讨

目的:研究miR-124对宫颈癌Hela细胞放射敏感性的影响及其机制。方法:将miR-124模拟物(mimics)、miR-124抑制物(inhibitor)分别转染至Hela细胞中。细胞周期实验检测细胞周期变化。克隆形成实验、细胞凋亡实验研究miR-124对Hela细胞放射敏感性的作用。双荧光素酶报告基因实验、RT-PCR和Western blot检测miR-124的直接靶基因。结果:miR-124模拟物组G0/G1期细胞比例高于对照组,S期细胞比例低于对照组(P均<0.05)。过表达miR-124可降低Hela细胞克隆形成能力,放射增敏比(SER)为1.49。流式细胞凋亡实验证明过表达miR-124可促进放射后细胞凋亡率(P<0.05)。抑制miR-124的表达结果则相反(P<0.05)。双荧光素酶报告基因实验、RT-PCR和Western blot实验证明信号传导与转录激活因子3(signal transducer and activator of transcription 3,STAT3)是miR-124的直接靶基因(P均<0.05)。结论:miR-124可能通过影响STAT3基因的表达来提高宫颈癌Hela细胞的放射敏感性。

miR-124在宫颈癌中的表达及对宫颈癌细胞增殖、迁移的影响

目的:探讨miR-124在宫颈癌中的表达,及其对宫颈癌细胞增殖、迁移的影响。方法:收集宫颈癌组织和癌旁组织各13例,qRT-PCR法检测miR-124的表达,免疫组化检测STAT3的表达。生物信息学技术预测miR-124的靶基因,双荧光素酶报告基因、qRT-PCR、Western blot实验验证。每种宫颈细胞随机分为三组,一组转染miR-124 mimics,一组不转染,一组转染miR-124 inhibitor。CCK-8实验检测细胞增殖能力,细胞划痕实验检测细胞迁移能力。结果:miR-124在宫颈癌组织和细胞系中表达均降低(P均<0. 05),STAT3在宫颈癌组织中的表达明显增高(P <0. 05)。STAT3是miR-124的直接靶基因,miR-124可靶向调节STAT3的mRNA和蛋白表达水平(P均<0. 05)。在Hela及Siha细胞中,miR-124 mimics转染组细胞增殖及迁移能力均降低(P均<0. 05),miR-124 inhibitor转染组细胞增殖及迁移能力均增加(P均<0. 05)。结论:miR-124在宫颈癌中低表达,可能通过靶向调节STAT3表达抑制宫颈癌细胞的增殖及迁移能力。

lncRNA在宫颈癌预后中的研究进展

宫颈癌是妇科常见肿瘤,近年来体内外研究发现长链非编码RNA(long non-coding RNA,lncRNA)的表达水平与宫颈癌预后密切相关。本文对近年来lncRNA在宫颈癌预后中的研究成果进行简要概述。

沉默长链非编码RNA POU5F1B抑制食管癌细胞增殖、侵袭和迁移

目的:探讨长链非编码RNA POU5F1B在食管癌细胞中的表达及临床意义。方法:采用实时定量PCR法比较POU5F1B在食管癌患者血浆和正常人血浆中的表达,检测POU5F1B在细胞系中的表达。敲除POU5F1B后,采用CCK-8和克隆形成试验评价沉默POU5F1B对细胞增殖的影响。采用Transwell和划痕实验检测POU5F1B对食管癌细胞侵袭和迁移的影响。结果:本研究中,我们发现POU5F1B在食管癌患者血浆中和细胞系中高表达。si-POU5F1B在体外能显著降低细胞增殖、侵袭和迁移能力。结论:本研究表明POU5F1B在食管癌中充当癌基因作用,为抗食管癌治疗提供了新的策略。